The second phase of Changzhou Qianhong Bio-pharma manufacturing project sees a further ¥1 billion devoted to increasing tablet and injection production.
According to the lentiviral vector manufacturer, which supplies vectors for Novartis’ Kymriah, the market is growing – and could be worth $800m by 2026.
The US FDA has approved Genentech’s auto-injector formulation of Actemra, which the firm says offers an additional administration option for patients and caregivers.
Funding of £7.3m will be provided across three initiatives, with the long-term aim of providing patients with access to cell and gene therapies at a faster rate.
Lonza Pharma & Biotech established itself in Israel, with the opening of a collaborative hub aiming to advance manufacturing technology for cell and gene therapy commercialization.
